Cxbladder is a non-invasive genomic urine test suite analyzing biomarker genes to rule out disease for bladder cancer surveillance.
View competitors
Pacific Edge is a cancer diagnostics company whose Cxbladder suite gives clinicians worldwide non-invasive urine tests for bladder cancer.
Pacific Edge is a cancer diagnostics company that uses genetic biomarkers in urine to develop and commercialize bladder cancer diagnostic and prognostic tests, including Cxbladder, a suite of non-invasive genomic urine tests for risk stratification, rule out, and surveillance of urothelial bladder cancer. It operates certified laboratories in New Zealand and the United States, and its intellectual property covers bladder, gastric, colorectal, and endometrial cancers and melanoma.
Cxbladder uses non-invasive collection with in-home sampling, sparing low-risk patients an invasive procedure. Pacific Edge offers Cxbladder directly in New Zealand, Australia, Singapore, and the United States, its largest market. It reaches other regions through a distributor network and sells Cxbladder to clinicians around the world.

Prolific Machines
Urology Diagnostics

IMBdx
imbdx.com

KDx Diagnostics
kdxdiagnostics.com

Cellens
cellensinc.com

OrisDX
orisdx.com

Exact Sciences
exactsciences.com

CpG Diagnostics
cpgdiagnostics.com

Geneoscopy
geneoscopy.com

Foresight Diagnostics
foresight-dx.com

Nuclidium
nuclidium.com
Predictive Biosciences
OncoCell MDx

Sansure Biotech
sansureglobal.com

PetDx

Early is Good
earlyisgood.com

Guardant Health
guardanthealth.com

Delve Bio
delve.bio

Lucid Diagnostics
luciddx.com

The Blue Box Biomedical Solutions
thebluebox.ai
Pacific Edge's most recent funding round was for NZ$36.1M (NZD) in June 2026.
As of Jun 3, 2026, Pacific Edge has disclosed funding of $21.3M (USD).